The biggest bottleneck in drug development is no longer discovery, it's in the clinic. Formation Bio's proprietary AI-native platform is changing drug development to bring new treatments to patients faster and more efficiently.
We catch up with Emily Gransky, who is shaping the talent strategy behind one of biotechs most exciting stories.
Emily previously shaped Flagship & RA Ventures TA strategies, and played a key role in scaling Bluebird Bio from 300 to 800 headcount.
During this episode, we discuss how the team are leveraging AI to drive efficiency and quality throughout the recruitment process. We also get Emily's take on the rapid evolution of AI and it's impact on biotech talent.
